Table 2.
Paired analyses of c-MYC amplification and copy number gain before and after neoadjuvant chemotherapy.
| Group | Both (+) | Only pre-NAC (+) | Only post-NAC (+) | Both (−) | |
|---|---|---|---|---|---|
| c-MYC amplification | Total (n = 119) | 5 (4.2) | 13 (10.9) | 4 (3.4) | 97 (81.5) |
| Chemo-resistant (n = 38) | 2 (5.3) | 3 (7.9) | 4 (10.5)* | 29 (76.3) | |
| Chemo-sensitive (n = 81) | 3 (3.7) | 10 (12.3) | 0 (0)* | 68 (84.0) | |
| c-MYC copy number gain | Total (n = 119) | 34 (28.6) | 30 (25.2) | 10 (8.4) | 45 (37.8) |
| Chemo-resistant (n = 38) | 13 (34.2) | 6 (15.8) | 3 (7.9) | 16 (42.1) | |
| Chemo-sensitive (n = 81) | 21 (25.9) | 24 (29.6) | 7 (8.6) | 29 (35.8) |
Numbers in parentheses indicate percentage.
NAC, neoadjuvant chemotherapy.
*P = 0.009.